Get startedLog in
    Picture of Ose Immunotherapeutics SA logo

    OSE — Ose Immunotherapeutics SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: OSE Immunotherapeutics Receives EUR 8.4 Mln In Public Funding For Lung Cancer Vaccine Candidate

    Picture of Ose Immunotherapeutics SA logoOse Immunotherapeutics SA
    10/04/2024 17:04
    April 10 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS RECEIVES €8.4 MLN IN PUBLIC FUNDING
 TO
SUPPORT THE REGISTRATION PHASE 3 CLINICAL TRIAL  OF CANCER
VACCINE TEDOPI® IN LUNG CANCER

Source text for Eikon:  urn:newsml:reuters.com:*:nGNEbYBBHH
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))

    Recent news on Ose Immunotherapeutics SA

    See all news